<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04549194</url>
  </required_header>
  <id_info>
    <org_study_id>2019PBMD06</org_study_id>
    <secondary_id>2020-A01658-31</secondary_id>
    <nct_id>NCT04549194</nct_id>
  </id_info>
  <brief_title>Contribution of L-Tyrosine to Recovery From Operational Strain on Return From External Operation</brief_title>
  <acronym>USOP</acronym>
  <official_title>Contribution of L-Tyrosine to Recovery From Operational Strain on Return From External Operation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Direction Centrale du Service de Santé des Armées</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Direction Centrale du Service de Santé des Armées</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Operational conditions amplify soldier's constraints and stress factors, upsetting individual&#xD;
      and collective adaptive landmarks. The soldier's resistance is strained by the high intensity&#xD;
      of stressors, by the long duration of exposure and by their cumulative effect.&#xD;
&#xD;
      This may lead to a state of &quot;operational strain&quot; that refers to chronic stress and the&#xD;
      allostatic load imposed by operational constraint.&#xD;
&#xD;
      The investigators believe that operational strain could manifest itself by a kind of&#xD;
      accelerated aging of the organism due to the increased allostatic load without sufficient&#xD;
      resource restoration (neurotransmitter precursors, partial and repeated sleep deprivation,&#xD;
      etc.).&#xD;
&#xD;
      This aging mechanism would be reversible after a sufficient period of resource restoration&#xD;
      (sleep, physical activity, adapted diet, etc.).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is composed of 2 groups, each of which is composed of 2 arms:&#xD;
External Operation group&#xD;
L-Tyrosine arm&#xD;
Placebo arm&#xD;
Rear Base group&#xD;
L-Tyrosine arm&#xD;
Placebo arm</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The pharmacist, carrying out the packaging and labelling of the treatment units, will ensure the blinding. Neither the participant nor the investigator will know what treatment is being administered.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Difference between the change in Burnout Assessment Tool (BAT) score following 1-month treatment in each arm</measure>
    <time_frame>After 1-month treatment</time_frame>
    <description>The Burnout Assessment Tool (BAT) is used to assess burn-out risk. The score ranges from 1 to 5, with higher scores indicating a higher risk of burn-out.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference between the change in catecholamine level following 1-month treatment in each arm</measure>
    <time_frame>After 1-month treatment</time_frame>
    <description>Catecholamine level will be measured in blood before during and after 1-month treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between the change in aminoacid level following 1-month treatment in each arm</measure>
    <time_frame>After 1-month treatment</time_frame>
    <description>Aminoacid level will be measured in blood before during and after 1-month treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between the change in zonulin level following 1-month treatment in each arm</measure>
    <time_frame>After 1-month treatment</time_frame>
    <description>Zonulin level will be measured in blood before during and after 1-month treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between the change in Brain-Derived Neurotrophic Factor (BDNF) level following 1-month treatment in each arm</measure>
    <time_frame>After 1-month treatment</time_frame>
    <description>BDNF level will be measured in blood before during and after 1-month treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between the change in gamma-aminobutyric acid (GABA) level following 1-month treatment in each arm</measure>
    <time_frame>After 1-month treatment</time_frame>
    <description>GABA level will be measured in blood before during and after 1-month treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between the change in Tumor Necrosis Factor Alpha (TNFα) level following 1-month treatment in each arm</measure>
    <time_frame>After 1-month treatment</time_frame>
    <description>TNFα level will be measured in blood before during and after 1-month treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between the change in Interleukin-6 (IL6) level following 1-month treatment in each arm</measure>
    <time_frame>After 1-month treatment</time_frame>
    <description>IL6 level will be measured in blood before during and after 1-month treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">312</enrollment>
  <condition>Stress, Psychological</condition>
  <arm_group>
    <arm_group_label>Tyrosine - External Operation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-month L-Tyrosine treatment following 4-month external operation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - External Operation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-month Placebo treatment following 4-month external operation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tyrosine - Rear Base</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-month L-Tyrosine treatment following 4 months at rear base</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Rear Base</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-month Placebo treatment following 4 months at rear base</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>A blood sample will be collected before during and after the treatment.</description>
    <arm_group_label>Placebo - External Operation</arm_group_label>
    <arm_group_label>Placebo - Rear Base</arm_group_label>
    <arm_group_label>Tyrosine - External Operation</arm_group_label>
    <arm_group_label>Tyrosine - Rear Base</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Tyrosine 500 Mg</intervention_name>
    <description>The participants will be administered 4 capsules of L-Tyrosine 500 mg per oral route daily over 1 month.</description>
    <arm_group_label>Tyrosine - External Operation</arm_group_label>
    <arm_group_label>Tyrosine - Rear Base</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychological questionnaires</intervention_name>
    <description>The participants will fill in several psychological questionnaires before, during and after treatment administration:&#xD;
Life Event Checklist&#xD;
Moral injury&#xD;
Posttraumatic Checklist&#xD;
Burnout Assessment Tool&#xD;
State-Trait Anger Expression Inventory-2&#xD;
Ruminative Response Scale - Reconsidered&#xD;
Deployment Risk and Resilience Inventory-2&#xD;
Questionnaire about tobacco use</description>
    <arm_group_label>Placebo - External Operation</arm_group_label>
    <arm_group_label>Placebo - Rear Base</arm_group_label>
    <arm_group_label>Tyrosine - External Operation</arm_group_label>
    <arm_group_label>Tyrosine - Rear Base</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Photoplethysmography</intervention_name>
    <description>Photoplethysmography recording will be performed before during and after the treatment.</description>
    <arm_group_label>Placebo - External Operation</arm_group_label>
    <arm_group_label>Placebo - Rear Base</arm_group_label>
    <arm_group_label>Tyrosine - External Operation</arm_group_label>
    <arm_group_label>Tyrosine - Rear Base</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route daily over 1 month.</description>
    <arm_group_label>Placebo - External Operation</arm_group_label>
    <arm_group_label>Placebo - Rear Base</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  From 18 to 65 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tyrosine intake within the previous 15 days&#xD;
&#xD;
          -  History of neurological or psychiatric disorder&#xD;
&#xD;
          -  History of nephrological or endocrine disorder or liver failure&#xD;
&#xD;
          -  Hereditary tyrosinemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Céline RAMDANI, MD, PhD</last_name>
    <phone>178651265</phone>
    <phone_ext>+33</phone_ext>
    <email>celine.ramdani@intradef.gouv.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anaïs MARMUSE</last_name>
    <phone>328382250</phone>
    <phone_ext>+33</phone_ext>
    <email>anais.marmuse@intradef.gouv.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Recherche Biomédicale des Armées</name>
      <address>
        <city>Brétigny-sur-Orge</city>
        <zip>91223</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline RAMDANI, MD, PhD</last_name>
      <phone>178651265</phone>
      <phone_ext>+33</phone_ext>
      <email>celine.ramdani@intradef.gouv.fr</email>
    </contact>
    <contact_backup>
      <last_name>Anaïs MARMUSE</last_name>
      <phone>328382250</phone>
      <phone_ext>+33</phone_ext>
      <email>anais.marmuse@intradef.gouv.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>L-tyrosine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress, Psychological</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

